Stockholm - Free Realtime Quote SEK

2cureX AB (publ) (2CUREX.ST)

Compare
0.4420 -0.0340 (-7.14%)
As of 3:14 PM GMT+2. Market Open.
Loading Chart for 2CUREX.ST
DELL
  • Previous Close 0.4760
  • Open 0.4740
  • Bid 0.4380 x --
  • Ask 0.4700 x --
  • Day's Range 0.4420 - 0.4740
  • 52 Week Range 0.2030 - 3.9900
  • Volume 11,842
  • Avg. Volume 68,458
  • Market Cap (intraday) 7.78M
  • Beta (5Y Monthly) 0.57
  • PE Ratio (TTM) --
  • EPS (TTM) -1.5000
  • Earnings Date Aug 22, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

2cureX AB (publ) operates as a medtech company in Europe. The company's principal product is IndiTreat, an IVD test, which helps to predict cancer patient's response and resistance to different drugs and select the appropriate treatment. It is also conducting various clinical programs for IndiTreat for colorectal, ovarian, and pancreatic cancers. The company was incorporated in 2006 and is based in Copenhagen, Denmark.

www.2curex.com

14

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 2CUREX.ST

View More

Performance Overview: 2CUREX.ST

Trailing total returns as of 8/29/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

2CUREX.ST
78.01%
OMX Stockholm 30 Index
8.04%

1-Year Return

2CUREX.ST
89.14%
OMX Stockholm 30 Index
19.16%

3-Year Return

2CUREX.ST
97.38%
OMX Stockholm 30 Index
9.18%

5-Year Return

2CUREX.ST
97.04%
OMX Stockholm 30 Index
69.44%

Compare To: 2CUREX.ST

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 2CUREX.ST

View More

Valuation Measures

Annual
As of 8/28/2024
  • Market Cap

    8.38M

  • Enterprise Value

    5.25M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    111.72

  • Price/Book (mrq)

    3.01

  • Enterprise Value/Revenue

    70.00

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -97.99%

  • Return on Equity (ttm)

    -174.78%

  • Revenue (ttm)

    1.98M

  • Net Income Avi to Common (ttm)

    -26.35M

  • Diluted EPS (ttm)

    -1.5000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.13M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -17.97M

Research Analysis: 2CUREX.ST

View More

Company Insights: 2CUREX.ST

Research Reports: 2CUREX.ST

View More

People Also Watch